Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.

ABSTRACT: The development of disease-modifying drugs and differential diagnostic agents is an urgent medical need in Parkinson's disease. Despite the complex pathophysiological pathway, the misfolding of alpha-synuclein has been identified as a putative biomarker for detecting the onset and progression of the neurodegeneration associated with Parkinson's disease. Identifying the most appropriate alpha-synuclein-based diagnostic modality with clinical translation will revolutionize the diagnosis of Parkinson's. Likewise, molecules that target alpha-synuclein could alter the disease pathway that leads to Parkinson's and may serve as first-in class therapeutics compared to existing treatment options such as levodopa and dopamine agonist that do not necessarily modify the disease pathway. Notwithstandin

SUBMITTER: Nwabufo CK 

PROVIDER: S-EPMC9281355 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature